

# CXCR4 Antibody (N-term)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AW5434

# **Product Information**

Application	WB, FC, IHC-P
Primary Accession	<u>P61073</u>
Reactivity	Human, Rat
Host	Rabbit
Clonality	Polyclonal
Calculated MW	39746
lsotype	Rabbit IgG
Antigen Source	HUMAN
<b>V</b> 1	0

# **Additional Information**

Gene ID	7852
Antigen Region	28-63
Other Names	C-X-C chemokine receptor type 4, CXC-R4, CXCR-4, FB22, Fusin, HM89, LCR1, Leukocyte-derived seven transmembrane domain receptor, LESTR, Lipopolysaccharide-associated protein 3, LAP-3, LPS-associated protein 3, NPYRL, Stromal cell-derived factor 1 receptor, SDF-1 receptor, CD184, CXCR4
Dilution	WB~~1:1000 FC~~1:25 IHC-P~~1:100~500
Target/Specificity	This CXCR4 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 28-63 amino acids from the N-terminal region of human CXCR4.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	CXCR4 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

#### **Protein Information**

Name	CXCR4
Function	Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by

	increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation (PubMed:10452968, PubMed:18799424, PubMed:24912431, PubMed:28978524). Involved in the AKT signaling cascade (PubMed:24912431). Plays a role in regulation of cell migration, e.g. during wound healing (PubMed:28978524). Acts as a receptor for extracellular ubiquitin; leading to enhanced intracellular calcium ions and reduced cellular cAMP levels (PubMed:20228059). Binds bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory response, including TNF secretion by monocytes (PubMed:11276205). Involved in hematopoiesis and in cardiac ventricular septum formation. Also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells. Involved in cerebellar development. In the CNS, could mediate hippocampal-neuron survival (By similarity).
Cellular Location	Cell membrane; Multi-pass membrane protein. Cell junction. Early endosome. Late endosome. Lysosome. Note=In unstimulated cells, diffuse pattern on plasma membrane. On agonist stimulation, colocalizes with ITCH at the plasma membrane where it becomes ubiquitinated. In the presence of antigen, distributes to the immunological synapse forming at the T- cell-APC contact area, where it localizes at the peripheral and distal supramolecular activation cluster (SMAC)
Tissue Location	Expressed in numerous tissues, such as peripheral blood leukocytes, spleen, thymus, spinal cord, heart, placenta, lung, liver, skeletal muscle, kidney, pancreas, cerebellum, cerebral cortex and medulla (in microglia as well as in astrocytes), brain microvascular, coronary artery and umbilical cord endothelial cells Isoform 1 is predominant in all tissues tested

## Background


Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation. Acts as a receptor for extracellular ubiquitin; leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. Involved in hematopoiesis and in cardiac ventricular septum formation. Also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells. Involved in cerebellar development. In the CNS, could mediate hippocampal-neuron survival. Acts as a coreceptor (CD4 being the primary receptor) for HIV-1 X4 isolates and as a primary receptor for some HIV-2 isolates. Promotes Env-mediated fusion of the virus. Binds bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory response, including TNF secretion by monocytes.

#### References

Herzog H.,et al.DNA Cell Biol. 12:465-471(1993). Jazin E.E.,et al.Regul. Pept. 47:247-258(1993). Federsppiel B.,et al.Genomics 16:707-712(1993). Loetscher M.,et al.J. Biol. Chem. 269:232-237(1994). Nomura H.,et al.Int. Immunol. 5:1239-1249(1993).


#### Images

AW5434 staining CXCR4 in Human spleen tissue sections by Immunohistochemistry (IHC-P paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval



was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody (1/25) for 1 hours at 37°C. A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.

Overlay histogram showing Jurkat cells stained with AW5434 (green line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min. The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (1:25 dilution) for 60 min at 37°C. The secondary antibody used was Alexa Fluor® 488 goat anti-rabbit lgG (H+L) (1583138) at 1/400 dilution for 40 min at 37°C. Isotype control antibody (blue line) was rabbit IgG1 (1µg/1x10^6 cells) used under the same conditions. Acquisition of >10, 000 events was performed.



All lanes : Anti-CXCR4 Antibody (N-term) at 1:1000 dilution Lane 1: human skeletal muscle lysates Lane 2: Jurkat whole cell lysates Lane 3: rat heart lysates Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L),Peroxidase conjugated at 1/10000 dilution Predicted band size : 40 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

# Citations

• Endoglin Is Essential for the Maintenance of Self-Renewal and Chemoresistance in Renal Cancer Stem Cells.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.